Abstract
Parasites are eukaryotic pathogens and largely include protozoa, helminths and arthropods that cause different diseases to human. Parasitic diseases have a significant impact on developing countries and it has raised the mortality rate to various millions per year. Despite the recent progress, no vaccines are presently available against any of the major parasitic infections of humans. Chemotherapy remains the only option for both clinical and control management. However, conventional drugs are present with features that limit their utility, such as high cost, poor compliance, drug resistance, low efficacy and poor safety. There is thus a clear need for new therapeutic agents against parasites infections.
Keywords: Anti-infective, anti-parasitic, helminths, natural products, parasite, protozoa.
Current Clinical Pharmacology
Title:Editorial (Thematic Issue: Development of Natural Products as Anti-Parasitic Agents)
Volume: 9 Issue: 3
Author(s): Monzote Lianet
Affiliation:
Keywords: Anti-infective, anti-parasitic, helminths, natural products, parasite, protozoa.
Abstract: Parasites are eukaryotic pathogens and largely include protozoa, helminths and arthropods that cause different diseases to human. Parasitic diseases have a significant impact on developing countries and it has raised the mortality rate to various millions per year. Despite the recent progress, no vaccines are presently available against any of the major parasitic infections of humans. Chemotherapy remains the only option for both clinical and control management. However, conventional drugs are present with features that limit their utility, such as high cost, poor compliance, drug resistance, low efficacy and poor safety. There is thus a clear need for new therapeutic agents against parasites infections.
Export Options
About this article
Cite this article as:
Lianet Monzote, Editorial (Thematic Issue: Development of Natural Products as Anti-Parasitic Agents), Current Clinical Pharmacology 2014; 9 (3) . https://dx.doi.org/10.2174/157488470903140806112509
DOI https://dx.doi.org/10.2174/157488470903140806112509 |
Print ISSN 1574-8847 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-3938 |
Related Articles
-
Current Options and Future Possibilities for the Treatment of Dyskinesia and Motor Fluctuations in Parkinson's Disease
CNS & Neurological Disorders - Drug Targets Stroke Subtypes and their Possible Implication in Stroke Prevention Drug Strategies
Current Vascular Pharmacology Administration of Exogenous Surfactant and Cytosolic Phospholipase A2α Inhibitors may Help COVID-19 Infected Patients with Chronic Diseases
Coronaviruses Culturally Informed Care of the Turkish-American Child, Adolescent, and Family
Adolescent Psychiatry Aliskiren: A New Drug for an Old Problem
Cardiovascular & Hematological Agents in Medicinal Chemistry ThermoTRP Channels in Nociceptors: Taking a Lead from Capsaicin Receptor TRPV1
Current Neuropharmacology Statins And Stroke
Current Medicinal Chemistry Brain Stimulation in Obsessive-Compulsive Disorder (OCD): A Systematic Review
Current Neuropharmacology Quality Control Optimization Solutions for Determination of Rutin in Supplements Containing Ginkgo Biloba Extract
Current Pharmaceutical Analysis Therapeutic Strategies for Treatment of Inflammation-related Depression
Current Neuropharmacology Susceptibility of Helicobacter pylori to Natural Products: Can Past Research Direct Future Drug Development?
Current Bioactive Compounds Cerebrospinal-fluid Alzheimer’s Disease Biomarkers and Blood-Brain Barrier Integrity in a Natural Population of Cognitive Intact Parkinson’s Disease Patients
CNS & Neurological Disorders - Drug Targets Milestones in Antihypertensive Drug Treatment
Current Pharmaceutical Design Overview of Hyperuricaemia and Gout
Current Pharmaceutical Design Cardiovascular Effects of Current and Future Anti-Obesity Drugs
Current Vascular Pharmacology An Overview of Galenic Preparation Methods for Medicinal Cannabis
Current Bioactive Compounds TNF alpha Inhibition as Treatment Modality for Certain Rheumatologic and Gastrointestinal Diseases
Endocrine, Metabolic & Immune Disorders - Drug Targets Melatonin in Antinociception: Its Therapeutic Applications
Current Neuropharmacology Leishmaniasis: History, Evolution of Treatment and the Need for New Drugs
Current Biotechnology Insight into Pain Modulation: Nociceptors Sensitization and Therapeutic Targets
Current Drug Targets